Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis

粘膜免疫生物学和风湿病发病机制中心

• 批准号: 10700077
• 负责人: Vernon Michael Holers
• 金额: $ 75.06万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-10 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10700077
• 关键词: Attention; Autoantigens; Autoimmune Diseases; Autoimmunity; Biological Markers; Blood specimen; CLIA certified; Cell Communication; Cells; Chronic; Clinical; Collaborations; Colorado; Communication; Computer Analysis; Consultations; Data; Data Analyses; Data Science; Data Science Core; Data Set; Development; Diagnostic; Direct Costs; Disease; Education; Environment; Epidemiology; Epithelium; Evolution; Funding; Future; Goals; Grant; Grant Review; Healthcare Systems; Human; Immunobiology; Immunologic Markers; Immunologic Techniques; Immunology; Individual; Inflammation; Inflammatory; Infrastructure; Institution; Investments; Letters; Medicine; Mesenchymal; Methodology; Methods; Mission; Molecular; Mucosal Immune Responses; Mucosal Immune System; Mucous Membrane; Newsletter; Online Systems; Outcome; Participant; Pathogenesis; Pathway interactions; Patient Care; Patients; Peripheral; Phase; Phenotype; Play; Population; Population Sciences; Population Study; Populations at Risk; Process; Program Development; Research; Research Personnel; Resources; Rheumatism; Rheumatoid Arthritis; Role; Sampling; Sampling Studies; Scholars Program; Science; Series; Services; Source; Spondylarthropathies; Study Subject; Systemic Lupus Erythematosus; Technology; Technology Assessment; Testing; Therapeutic; Tissue Sample; Tissues; Training; Translating; Translations; Universities; biobank; biomarker development; biomarker identification; career; clinical care; cohort; commercialization; complex data; data management; design; direct patient care; discount; disease classification; dysbiosis; early detection biomarkers; human disease; improved; improved outcome; innovation; insight; interest; member; metabolome; metabolomics; microbial; microbiome; microbiome analysis; mid-career faculty; mucosal site; novel; novel marker; novel strategies; novel therapeutics; outreach; peripheral blood; personalized medicine; pre-clinical; prevent; professor; programs; recruit; research and development; single cell technology; skills; social media; symposium; systemic autoimmunity; systemic inflammatory response; therapy development

A substantial cadre of investigators at the University of Colorado are focused on characterizing the molecular origins and causal mechanisms that drive the initiation and preclinical phases of rheumatic and autoimmune diseases. One of the most important outcomes of those efforts has been the demonstration in populations at- risk for future disease that dysbiosis and chronic inflammation at mucosal sites can promote the initial local development of disease-specific loss of tolerance to autoantigens. Ultimately, this process leads to systemic autoimmunity and the development of diseases including rheumatoid arthritis (RA) and spondyloarthroarthritis (SpA). Building on that concept with unique at-risk populations and an extensive programmatic infrastructure, a P30 Rheumatic Disease Research Resource Center (RDRRC) entitled “Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis” is proposed. Included in the Center are an Administrative Core, a Population and Data Sciences Core, and a Mucosal Immunobiology Core. This Center is specifically designed to facilitate studies of human disease pathogenesis that incorporate the broad range of mucosal and systemic immunologic techniques, as well as develop new approaches, to study these integrated mechanisms in already recruited cohorts of individuals throughout the preclinical and then clinically active phases of disease. The Center includes 43 internal and external members who have in aggregate $77M in related annual direct cost grant funding. In addition to providing access to stored biospecimens and data from ongoing population studies, the Center will provide consultative and member discount mechanisms for all of the critical aspects of cohort development, epidemiologic assessment, data management and data analyses. In addition, the Center will provide members access to technologies that focus on analyses of the microbiome and microbial:cell interactions, as well as informative mucosal and peripheral immune biomarkers. The Center will build on a recent $80M investment from the Dean to fund four other relevant programs with which this Center will interact. Dr. Michael Holers, Professor of Medicine and Immunology, will serve as the Center Director, and Dr. Kristi Kuhn, Associate Professor of Medicine, will serve as the Associate Director. Both will interact with Advisory and Executive Committees, and in the latter will be joined by Core Directors and Co-Directors with domain expertise. As a key component of the mission of the Center, a Pilot & Feasibility Grants Program will be developed with substantial institutional support. Additional Enrichment Program activities will include a seminar series, technology assessment series, and an annual symposium. A major focus will be on early career investigator development through enhanced Core access as well as Grants Review and a Scholars Programs. Social media, web-based outreach and newsletters will provide comprehensive communication. Finally, a Patient Impact Program will be utilized for the assessment and enhanced translation of novel biomarkers and therapeutically relevant RDRRC discoveries into direct patient care with the goal to improve outcomes.

科罗拉多大学的大量研究人员致力于表征分子 驱动风湿和自身免疫的主动性和临床前阶段的起源和因果机制 疾病。这些努力最重要的结果之一是人口中的示威 未来疾病的风险会在粘膜部位的营养不良和慢性感染可以促进最初的局部局部 疾病特异性丧失对自身抗原的耐受性的发展。最终，此过程导致系统性 自身免疫性和包括类风湿关节炎（RA）和赞助性关节炎在内的疾病的发展 （温泉）。以独特的高风险人群和广泛的程序化基础架构为基础 P30风湿病研究资源中心（RDRRC）题为“粘膜免疫生物学中心 提出了“提出的”和风湿病的发病机理。中心包括行政核心，一个 人群和数据科学核心以及粘膜免疫生物学核心。该中心是专门设计的 为了促进人类疾病发病机理的研究，这些发病机理融合了各种粘膜和全身性 免疫学技术以及开发新方法，以研究这些综合机制 在整个临床前，然后是疾病的临床活跃阶段的招募人群。 中心包括43个内部和外部成员，这些成员总计7700万美元相关的年度直接费用 赠款。除了提供对正在进行人群的存储生物测量和数据的访问 研究中心将为所有关键方面提供咨询和会员折扣机制 队列开发，流行病学评估，数据管理和数据分析。此外，中心 将为成员访问专注于微生物组和微生物分析的技术：细胞 相互作用，以及信息丰富的粘膜和周围免疫生物标志物。中心将建立在 该院长最近的8000万美元投资为该中心互动的其他四个相关计划提供资金。 医学和免疫学教授迈克尔·霍尔斯（Michael Holers）博士将担任中心主任，克里斯蒂（Kristi）博士 医学副教授库恩（Kuhn）将担任副主任。两者都将与咨询互动 和执行委员会，并将在后者中与核心董事和联合导演一起加入 专业知识。作为中心任务的关键组成部分，将是一项飞行员和可行性赠款计划 以大量的机构支持开发。额外的丰富计划活动将包括开创性的 系列，技术评估系列和年度研讨会。重点是早期职业 通过增强的核心访问以及赠款审查和学者计划的研究人员开发。 社交媒体，基于网络的外展和新闻通讯将提供全面的沟通。最后，一个 患者影响计划将用于评估和增强新型生物标志物的翻译和增强 治疗相关的RDRRC发现直接患者护理，以改善预后的目标。

项目成果

Antinuclear Antibodies Are Associated with an Increased Risk of Diffuse Large B-Cell Lymphoma.

• DOI: 10.3390/cancers15215231
• 发表时间: 2023-10-31
• 期刊: CANCERS
• 影响因子: 5.2
• 作者: Frost, Eleanor;Hofmann, Jonathan N.;Huang, Wen-Yi;Parks, Christine G.;Frazer-Abel, Ashley A.;Deane, Kevin D.;Berndt, Sonja I.
• 通讯作者: Berndt, Sonja I.